A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autologous Hemopoietic Stem Cell Support and Maintenance Treatment With Interferon-a Versus Thalidomide Versus Thalidomide / Velcade in Untreated Patients With Multiple Myeloma Less Than 65 Yrs Old
Latest Information Update: 05 Dec 2019
At a glance
- Drugs Bortezomib (Primary) ; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Interferon alpha-2b; Melphalan; Prednisone; Thalidomide; Vincristine
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms Pethema/GEM Study
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 A matching adjusted indirect comparison of the VTd-mod dose from recent clinical trials versus the dose included in the label was performed to understand the effect on efficacy of modified VTd dosing for patients with NDMM who are transplant eligible; results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.